© 2019 Peptilogics  I  All Rights Reserved

News & Updates

Peptilogics is attending the 37th Annual J.P. Morgan Healthcare Conference on January 7-10, 2019

Peptilogics, a development stage company utilizing its innovative peptide platform to treat multidrug-resistant bacterial infections, today announced it recently held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of PLG0206 for the treatment of prosthetic joint infections (PJI). PJI is one of the most challenging complications of joint arthroplasty and a serious, life-threatening condition with few...

Builds on PLG0206 studies published in Nature Scientific Reports. 
Company to present at BIO in Boston on June 5.

Peptilogics, a development stage company utilizing its innovative peptide platform to treat multidrug-resistant bacterial infections, today announced that its lead compound PLG0206 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for the treatment of prosthetic joint infections (PJI).

PJI is one of the most challenging complicati...

Please reload